Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/0008-5472.can-19-2787
Abstract: Deregulated T-cell receptor signaling is a critical molecular event in angioimmunoblastic T-cell lymphoma and can be targeted with dasatinib. Recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with loss-of-function mutations in TET2… read more here.
Keywords: cell lymphoma; angioimmunoblastic cell; treatment; cell ... See more keywords